Close Menu

GenomeWeb

The wastewater analytics firm will work with the two government agencies to analyze samples from treatment plants across the US for SARS-CoV-2 viral elements.

Several analysts said that the decision by UHC, the largest private payor in the US, will especially benefit Natera.

The firm plans to raise $25 million in a public offering of shares of its common stock and $75 million in a senior notes offering to institutional buyers.

The company sells miniaturized mass spectrometers and microfluidic separations systems for use in applied markets and life science and drug research.

The firm is also pursuing advances in its manufacturing and ordering processes that it says will help it scale to $500 million in annual revenues.

The UK has given emergency authorization for Pfizer and BioNTech's SARS-CoV-2 vaccine, the Associated Press reports.

A US advisory committee says healthcare workers and nursing home residents should be prioritized to receive a SARS-CoV-2 vaccine, according to the Financial Times.

The Wall Street Journal reports North Korean hackers have targeted half a dozen companies developing SARS-CoV-2 vaccines.

In Cell this week: long-term SARS-CoV-2 shedding, examination of the effects of a coronavirus spike protein mutation, and more.

The tumor microenvironment (TME) is comprised of an array of cell types, including immune and inflammatory cells, adipose cells, neuroendocrine cells, and cancer-associated fibroblasts. Additionally, blood and lymphatic vascular networks and extracellular matrix components create a diverse and multifaceted situation. Understanding how all of these elements interact requires the ability to distinguish individual cell types--something that is difficult to do using bulk cell approaches. Single cell gene expression analyses offer a high-resolution understanding of the TME.

Carrier screening to detect the presence of heritable genetic defects has been an important element of reproductive health strategies for over 50 years. Until recently, however, the practice has been restricted to a limited number of single-gene tests offered mainly to higher-risk individuals or populations based on race, ethnicity, or ancestry. But the landscape of carrier screening and its role in reproductive health are changing fast.